Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH001 in Moderate to Severe COPD
NCT07519499Phase 2Not yet recruiting
- Sponsor
- Kanova
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of xkh001 in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Kanova. Primary endpoints: Primary Outcome 1 at 36 weeks and Primary Outcome 2 at 28 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
xkh001
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07519499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07519499.